Pharmaceutical intermediates

Relugolix Intermediates

7 pharmaceutical intermediates for Relugolix. Indication: Prostate Cancer; Leiomyoma.

About Relugolix

7 intermediates currently listed for Relugolix. Request specifications, documentation or a quotation for any item below.

Relugolix intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-nitrophenyl)thiophene-3-carboxylic acid	1589503-95-6	/	/
3-AMINO-6-METHOXYPYRIDAZINE	7252-84-8	/	/
ethyl 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate	308831-94-9	/	/
2-AcetaMido-4,5-diMethylthiophene-3-carboxylic acid	2591260-09-0	/	/
3-Thiophenecarboxylic acid, 2-[[(2,6-difluorophenyl)methyl](propoxycarbonyl)amino]-4-[(dimethylamino)methyl]-5-(4-nitrophenyl)-, ethyl ester	2591260-08-9	/	/
3-Thiophenecarboxylic acid,5-(4-aminophenyl)-2-[[(2,6-difluorophenyl)methyl](ethoxycarbonyl)amino]-4-[(dimethylamino)methyl]-,ethylester, hydrochloride (1:2)	2768834-98-4	/	/
2-[(2,6-Difluorobenzyl)ethoxycarbonylamino]-4-((dimethylamino)methyl)-5-(4-nitrophenyl)thiophene-3-carboxylic acid ethyl ester	1589503-97-8	/	/

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态